Zusammenfassung
Eine 64-jährige Typ-2-Diabetikerin wird aktuell mit einem BOT mit Insulin Glargin und Metformin behandelt. Ihre jüngere Schwester ist rezent an einem Mammakarzinom verstorben. Sie hat jetzt Angst. Was sagen die Studien?
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang YuP, Ryden LE, Pirags V, Spinas GA, Birkeland KI, Ratner RE, Marin-Neto JA, Keltai M, Riddle MC, Bosch J, Yusuf S, Gerstein HC, Investigators OT (2014) The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes care 37(5):1360–1366. https://doi.org/10.2337/dc13-1468
Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777. https://doi.org/10.1007/s00125-009-1440-6
Gallagher EJ, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D (2016) Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia 59(9):2018–2025. https://doi.org/10.1007/s00125-016-4000-x
Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744. https://doi.org/10.1007/s00125-009-1418-4
Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754. https://doi.org/10.1007/s00125-009-1444-2
Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121(4):856–862. https://doi.org/10.1002/ijc.22717
Stammberger I, Essermeant L (2012) Insulin glargine: a reevaluation of rodent carcinogenicity findings. Int J Toxicol 31(2):137–142. https://doi.org/10.1177/1091581811431111
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. The Cochrane database of systematic reviews (7):CD006383. https://doi.org/10.1002/14651858.cd006383.pub2
Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S (2017) Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol: official J American Society of Clinical Oncology 35(32):3647–3653. https://doi.org/10.1200/JCO.2017.73.4491
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kihm, L. (2018). Fall 58: Spätschäden – 64 Jahre, ♀, DM Typ 2, Krebsrisiko. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_58
Download citation
DOI: https://doi.org/10.1007/978-3-662-55972-7_58
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55971-0
Online ISBN: 978-3-662-55972-7
eBook Packages: Medicine (German Language)